Sydney, June 25, 2007 (ACN Newswire) - Life Therapeutics (ASX: LFE) today provided details of an agreement (the “Agreement”) with Kedrion S.p.A (“Kedrion”), a leading European speciality pharmaceutical company and Italy’s largest fractionator, that will enable the company to deliver on its strategy to become a vertically integrated operator. Under the terms of the Agreement, Life Therapeutics will take up a 5.5% equity stake in Kedrion and will divest assets from its Life Sera business into a new joint venture company with Kedrion (“Newco”).
